Wells Fargo assumed coverage of Xenon Pharmaceuticals (XENE) with an Overweight rating and $48 price target The company expects the readout of its Phase 3 X-TOLE2 study involving lead asset, azetukalner, in Focal Onset Seizures in early 2026, and the firm believes that azetukalner is likely to succeed in X-TOLE2 given the strong Phase 2 data, the analyst tells investors in a research note. The 10mg dose worked in Phase 2, implying some room for efficacy pullback in Phase 3, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals’ Earnings Call Highlights Progress and Promise
- Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees
- Xenon: Promising Outlook with Strong Financial Health and Expanding Research Initiatives
- Xenon Pharmaceuticals price target lowered to $55 from $57 at RBC Capital
- Xenon’s Promising Pipeline and Strategic Progress Justify Buy Rating